相关实验视频

Updated: Jul 16, 2026

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

维尔马纳斯阿尔法可以成为阿尔法曼诺症的下一个广泛的潜在治疗方法吗?

Sundus Abdul Ghani¹, Sheeba Burney¹, Hassan Ul Hussain¹

¹Dow University of Health Sciences, Karachi.

International journal of surgery (London, England)

|June 23, 2023

概括

阿尔法曼诺症 (AM) 是一种罕见的遗传性疾病. 早期诊断和用velmanase alfa的酶替代疗法显示出对管理非神经症状的前景.

科学领域:

生物化学生物化学
遗传学遗传学是一个
儿科儿科儿科

背景情况:

阿尔法-曼诺症 (AM) 是一种自体逆性溶酶体储存障碍,由阿尔法-曼诺酶缺乏引起.
亚米有各种不同的临床表现,包括免疫缺陷,骨和面部异常,听力障碍和智力障碍.
诊断依赖于在核细胞中识别缺陷的α-曼诺酶活性,这是由于潜伏性疾病进展至关重要的.

研究的目的:

审查当前对阿尔法-曼诺索症的理解.
讨论诊断方法和治疗选择,包括酶替代疗法 (ERT).
突出velmanase alfa在AM治疗中的作用和潜力.

主要方法:

对Alpha-mannosidosis诊断和治疗的文献评论.
对velmanase alfa疗效和安全性的临床试验数据的分析.
讨论当前的治疗策略和未来的研究需求.

主要成果:

一种重组α-曼诺酶的velmanase alfa已被批准用于治疗轻度至中度AM的非神经学方面.
临床试验表明,velmanase alfa对AM患者的积极影响.
延迟诊断和开始治疗有助于累积发病率.

结论:

早期诊断AM对于有效管理至关重要.
维尔曼酶α为AM中ERT提供了一个治疗选择.
需要提高认识和进一步的大规模试验来确认长期的安全性和有效性.

更多相关视频

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...